Your browser doesn't support javascript.
loading
Male breast cancer: a multicenter study to provide a guide for proper management.
Lissidini, Germana; Nicosia, Luca; Sargenti, Manuela; Cucchi, Maria Cristina; Fabi, Alessandra; Falco, Giuseppe; Gardani, Marco; Grilz, Greta; Maugeri, Ilaria; Murgo, Roberto; Neri, Alessandro; Pellini, Francesca; Sensi, Cristiana; Scomersi, Serena; Taffurelli, Mario; Bagnardi, Vincenzo; Oriecuia, Chiara; Pagan, Eleonora; Sangalli, Claudia; Dessena, Massimo; Veronesi, Paolo; Galimberti, Viviana.
Afiliação
  • Lissidini G; Division of Breast Surgery, IEO, European Institute of Oncology IRCCS, 20141, Milan, Italy.
  • Nicosia L; Division of Breast Radiology, IRCSS, IEO European Institute of Oncology, 20141, Milan, Italy. luca.nicosia@ieo.it.
  • Sargenti M; Division of Breast Surgery, IEO, European Institute of Oncology IRCCS, 20141, Milan, Italy.
  • Cucchi MC; Breast Surgery Unit, Bellaria-Maggiore Hospital, Bologna, Italy.
  • Fabi A; Precision Medicine Unit in Senology, Fondazione Policlinico Universitario A. Gemelli IRCCS Rome, Rome, Italy.
  • Falco G; Breast Surgery Unit AUSL-IRCCS, Reggio Emilia, Italy.
  • Gardani M; Department of Surgery, Breast Unit Piacenza, Guglielmo da Saliceto Hospital, Piacenza, Italy.
  • Grilz G; Breast Surgery Unit Chirurgia Senologica Breast Unit Ospedale Cottolengo, Turin, Italy.
  • Maugeri I; Breast Surgery Unit, Fondazione IRCCS Istituto Nazionale Tumori Di Milano, Milan, Italy.
  • Murgo R; Breast Surgery Unit, IRCCS Ospedale Casa Sollievo Della Sofferenza, San Giovanni Rotondo, Foggia, Italy.
  • Neri A; Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.
  • Pellini F; Complex Operative Unit (UOC) Breast Surgery, Breast Unit, Oncology Department Azienda Ospedaliera, Universitaria Integrata (AOUI) Verona, Verona, Italy.
  • Sensi C; Breast Surgery Unit, Ospedale Belcolle, Viterbo, Italy.
  • Scomersi S; Division of General Surgery, Breast Unit, Hospital of Cattinara, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy.
  • Taffurelli M; Breast and General Surgery Unit, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy.
  • Bagnardi V; Department of Statistics and Quantitative Methods, University of Milano-Bicocca, Milan, Italy.
  • Oriecuia C; Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
  • Pagan E; Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
  • Sangalli C; Department of Statistics and Quantitative Methods, University of Milano-Bicocca, Milan, Italy.
  • Dessena M; Clinical Trial Office, European Institute of Oncology IRCCS, 20141, Milan, Italy.
  • Veronesi P; Breast Surgery Unit, Azienda Ospedaliero-Universitaria Di Cagliari, Cagliari, Italy.
  • Galimberti V; Division of Breast Surgery, IEO, European Institute of Oncology IRCCS, 20141, Milan, Italy.
Article em En | MEDLINE | ID: mdl-38896332
ABSTRACT

INTRODUCTION:

To offer an extensive retrospective experience on the management of male breast cancer.

METHODS:

A multicenter retrospective observational cohort study was conducted, including male patients diagnosed with breast cancer (invasive or in situ) in 12 Italian breast units from January 1975 to December 2019. Patients aged 18 years or older were assessed for eligibility. Exclusion criteria were metastatic cancer at diagnosis, previous cancer(s), received neoadjuvant treatment, incomplete data on (neo) adjuvant treatment(s), and/or follow-up data. Data on radiological examinations, demographic characteristics, risk factors, histological features, receptor status, treatments, and follow-up were collected.

RESULTS:

In a series of 671 male patients with breast cancer assessed for eligibility, 403 (28 in situ and 375 invasive neoplasms) were included in the study. All included patients underwent surgery. The median age at surgery was 63.8 years (IQR 56.1-72.1). In 68% of cases, patients underwent echography, and in 55.1%, a mammography. Most patients were ER and PR positive (63.8%), HER2 negative (80.4%), with high (≥ 20%) Ki67 values (61.3%), and luminal B subtype (51.1%). The 10-year overall survival was 73.6% (95% CI 67.0-79.1) for invasive breast cancer and 90% (95% CI 65.6-97.4) for in situ breast cancer. In patients with invasive breast cancer, at univariable analysis, having a G3 tumor (vs. G1), pT2/3/4 (vs. pT1), pN2/3 (vs. pN0), luminal B subtype with Ki67 ≥ 20% (vs. Luminal A), were significantly associated with a higher risk of death. In multivariable analyses, pT2/3/4 (vs. pT1) remained significantly associated with a higher risk of death (HR 3.14, 95% CI 1.83-5.39), and having a HER2 positive or a triple-negative subtype (vs. Luminal A) was also significantly associated with a higher risk of mortality (HR 4.76, 95% CI 1.26-18.1).

CONCLUSION:

Male breast cancer is a rare disease, the better understanding of which is necessary for a more effective diagnostic and therapeutic approach.
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Breast Cancer Res Treat Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Breast Cancer Res Treat Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Itália